Biovie Inc (BIVI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biovie Inc (BIVI) has a cash flow conversion efficiency ratio of -0.477x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.44 Million) by net assets ($15.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BIVI market cap for the company's overall valuation and market capitalisation.
Biovie Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Biovie Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biovie Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biovie Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Biovie Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Entero Therapeutics, Inc.
NASDAQ:ENTO
|
-0.010x |
|
CytoMed Therapeutics Limited Ordinary Shares
NASDAQ:GDTC
|
-0.299x |
|
Pila Pharma AB
ST:PILA
|
-0.095x |
|
CoinSmart Financial Inc
NEO:SMRT
|
-0.279x |
|
Polar Capital Holdings plc
LSE:POLR
|
0.460x |
|
Akkhie Prakarn Public Company Limited
BK:AKP
|
0.036x |
|
Prismaflex Intl
PA:ALPRI
|
0.196x |
|
Skyline Investment S.A.
WAR:SKL
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Biovie Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Biovie Inc from 2013 to 2025. View BIVI share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $19.01 Million | $-19.03 Million | -1.001x | +44.47% |
| 2024-06-30 | $15.51 Million | $-27.95 Million | -1.802x | +31.32% |
| 2023-06-30 | $15.34 Million | $-40.25 Million | -2.624x | +49.28% |
| 2022-06-30 | $3.67 Million | $-18.99 Million | -5.173x | -149.94% |
| 2021-06-30 | $5.05 Million | $-10.45 Million | -2.070x | -2832.88% |
| 2020-06-30 | $-21.50 Million | $-1.63 Million | 0.076x | +106.45% |
| 2019-06-30 | $2.13 Million | $-2.50 Million | -1.174x | +78.99% |
| 2018-06-30 | $111.20K | $-621.34K | -5.588x | -936.97% |
| 2017-06-30 | $1.16 Million | $-623.62K | -0.539x | -530.93% |
| 2016-06-30 | $1.92 Million | $-163.63K | -0.085x | -107.07% |
| 2015-06-30 | $-54.12K | $-65.38K | 1.208x | +219.80% |
| 2014-06-30 | $171.39K | $-172.83K | -1.008x | -4828.56% |
| 2013-06-30 | $490.70K | $-10.04K | -0.020x | -- |
About Biovie Inc
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to mo… Read more